Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07153867
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 4053615 (1977-10-01), Boyle et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5955476 (1999-09-01), Muller et al.
patent: 6114355 (2000-09-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6306879 (2001-10-01), Germann et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6429212 (2002-08-01), Hashimoto
patent: 6458810 (2002-10-01), Muller et al.
patent: 6476052 (2002-11-01), Muller et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6667316 (2003-12-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 92/14455 (1992-09-01), None
patent: WO 9803502 (1998-01-01), None
“New Cancer Drugs No ‘Magic bullet’, but Promising”, Reuters News, 2001.
Strategy Aims to Starve Rather Than Poison Cancer, Daniel Haney, 1999.
Cecil TextBook of Medicine, 20th Edition, vol. 1, 1997.
“Angiogenesis and the Role of Epigenetics in Metastasis”, Coomber et al., Clinical a& Experimental Metastasis, 20:215-227, 2003.
“Thalidomide and Prednisolone Inhibit Growth Factor-INduced Human Retinal Pigment Epithelium Cell Proliferation in Vitro”, Kaven et al., abstract, vol. 215, No. 4, 2001.
“Age-Related Macular Degeneration”, Drug Therapy, vol. 342, No. 7, pp. 483-492, 2000.
“A Common Pharmacore for Taxol and the Epothilones Based on the Biological Activity of a Taxane Molecule Lacking a C-13 Side Chain”, He et al., Biochemistry 2000, 39, pp. 3972-3978.
“Thalidomide Analogs and PDE4 Inhibition”, Muller et al., Biorganic & Medicinal Chemistry Letters, 1998, pp. 2669-2674.
Montrucchio et al., 1994,Tumor Necrosis Factor α-induced Angiogenesis Depends on In Situ Platelet-activating Factor Biosynthesis, J. Exp. Med. 180:337-382.
Conner Barry P.
D'Amato Robert J.
Hunsucker Kimberly A.
Pribluda Victor
Rougas John
Celgene Corporation
Jones Day
Kwon Brian
LandOfFree
Use of nitrogen substituted thalidomide analogs for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of nitrogen substituted thalidomide analogs for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nitrogen substituted thalidomide analogs for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716272